Reviewer's report

Title: Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: A randomized, double-blind, placebo-controlled trial

Version: 2 Date: 10 May 2012

Reviewer: Per Hellman

Reviewer's report:

The study design by Tomaschitz et al. is thorough and detailed in an interesting subject. The Power analysis seems well performed, planned statistics sound and support from a pharmaceutical company ensures the initiation of the study.

A minor point would be that patients with hereditary pHPT should be excluded, and most likely patients under the age of 30 or 40, in order to safely avoid such patients. If DNA anyway is sampled, why not also perform MEN1-analysis on genomic DNA to exclude these patients?

Otherwise the study is well-designed and would be informative for the medical community.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have no competing interests